Sire Bioscience Inc. (“SIRE”) (CSE:SIRE, OTC:BLLXF, FSE:BR1B) (“Sire” or the “Company”) is pleased to announce that the construction has officially begun on the Company’s 50-Acre Leamington, Ontario property (the “Property”).

The first phase will result in the build out of 7,000 square feet of indoor space, inclusive of 2,000 square feet of canopy with the required security and supportive rooms. This phase will also see the installation of 2,900 linear feet of fencing expected to commence on December 9, 2019. The indoor secured storage area will also support SIRE’s outdoor grow initiative. Once the indoor and outdoor construction is complete, SIRE will submit an application to file for its indoor and outdoor cannabis cultivation licenses with Health Canada. To utilize the already acquired Industrial Hemp Licence, SIRE will also be planting high yielding CBD strains of hemp cannabis on the remainder of the acreage. The Company plans to start growing both indoor and outdoor areas in the new year.


“We’re excited to move forward quickly,” says Brian Polla, SIRE’s CEO. “This development makes for a very exciting time as we close in on our definitive agreement with Fusion Nutrition, Incorporated, executing on our House of Brands strategy as we enter Cannabis 2.0.”

A Prime Location for Cannabis Cultivation

Leamington, Ontario is nestled in an area known as the Sun Parlour of Canada. With warmer-than-average temperatures, this region delivers high-yield crops and is home to over 60% of Ontario’s greenhouses. In fact, Leamington has the largest concentration of greenhouses in North America and boasts a $3 billion agribusiness sector.

SIRE’s Property contains 137,088 square feet of greenhouse space and 40 acres of outdoor growing area. Before scaling to maximum growing output, SIRE will begin cultivating high THC strains on three acres of land.

“We’re taking this strategic and sustainable approach so we can understand the capabilities of the land and scale our business responsibly,” explains Polla. “Our priorities are efficiency, scalability, and long-term shareholder value. To that end, we are extremely practical in our operations and creating multiple revenue streams in a yet to be defined market which will give us the ability to be nimble and maneuver quickly knowing that as growing commoditizes, ‘brand’ will win in the end.”

Consumer Demand Continues

Consumer demand for cannabis shows no signs of slowing down. Analysts predict that legal cannabis sales may reach $4.7 billion by 2023, up from about $570 million in 2018.

As construction on the Company’s Property progresses, SIRE will continue to explore unique strains and product offerings to appeal to a wide variety of cannabis consumers. The site will also allow for future expansion opportunities.

SIRE will be documenting the process on their social platforms. Follow along @sirebioscience.

About Sire Bioscience

SIRE’s principal business activity is to engage in the investment, production of, and sale of hemp. Its mission is to execute on brand offerings that connect with people and build top of mind awareness.

SIRE is headquartered in Toronto, Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, logistics, and renewable energy. It has secured a state-of-the-art agricultural facility in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada.

FOR INFORMATION, CONTACT:

Sire Bioscience Inc.

E: ir@sirebioscience.com

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Information Cautionary Statement

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Click here to connect with Sire Bioscience (CSE:SIRE) for an Investor Presentation.

Source

Strong Innovation Pipeline Continues to Drive Market Share Growth
Broken Coast’s First Foray into Cannabis 2.0
Solei Introduces First Limited Release Vape on the Market
Solei, RIFF, Good Supply and B!NGO Expand Product Offerings

Aphria Inc. (” Aphria ” or the ” Company “) ( TSX: APHA and NASDAQ: APHA ), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its 510 Vape offering across its award-winning adult-use brand portfolio.

Keep reading... Show less

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1 2020 DEADLINE . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf Solutions“, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide the following commercial and intellectual property update:

Cannabis Extraction Agreement with White Label Producer

Keep reading... Show less

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has closed today its previously announced “bought deal” short form prospectus offering of units (“ Unit s ”), including the exercise in full of the over-allotment option (the “ Offering ”).

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit: https://www.cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/

Keep reading... Show less